Q-omics provides the consensus-scored MUC3A profile across patient tissues and cancer cell-line models. MUC3A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MUC3A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MUC3A RNA expression shows 13,518 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, and ESCA as cancer lineages where MUC3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC3A survival associations across molecular data types. MUC3A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC3A RNA expression–survival associations across cancer types. High MUC3A expression shows unfavorable associations in KIRC, MESO, BRCA, UVM, LGG and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MUC3A RNA expression.
This table summarizes MUC3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MUC3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC3A shows lower tumor expression in BRCA and higher tumor expression in KIRC, HNSC, LUAD, KIRP and STAD. The KIRC box plot shows higher MUC3A RNA expression in tumor versus normal tissue (log2 FC = +1.690, t-test p < 0.001).
This table shows molecular features associated with MUC3A in patient tissues and cancer cell lines. In patient samples, MUC3A shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
